Pfizer and Clear Creek Bio, a biotech startup based in Cambridge, Massachusetts, have partnered to develop a new COVID-19 treatment they hope will provide greater efficacy as the virus evolves and proves increasingly resistant to current treatments. The agreement is to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro)